Takeda Pharmaceutical Li... (TKPHF)
PNK: TKPHF
· Real-Time Price · USD
26.30
0.00 (0.00%)
At close: May 14, 2025, 3:11 PM
Takeda Pharmaceutical Revenue Breakdown
| Period Ending | Mar 31, 2024 | Mar 31, 2023 | Mar 31, 2022 | Mar 31, 2021 | Mar 31, 2020 |
|---|---|---|---|---|---|
| Adcetris Revenue | 109.42B | 83.94B | 69.19B | 59.43B | 52.67B |
| Adcetris Revenue Growth | +30.37% | +21.31% | +16.42% | +12.83% | n/a |
| Adderall XR Revenue | 41.76B | 118.19B | 118.49B | 128.53B | 24.3B |
| Adderall XR Revenue Growth | -64.67% | -0.26% | -7.81% | +428.84% | n/a |
| Advate Revenue | 122.91B | 66.55B | 60.73B | 57.58B | 157.86B |
| Advate Revenue Growth | +84.68% | +9.60% | +5.46% | -63.52% | n/a |
| Adynovate/Adynovi Revenue | 66.31B | 121.45B | 90.03B | 784M | 67.22B |
| Adynovate/Adynovi Revenue Growth | -45.40% | +34.89% | +11384.06% | -98.83% | n/a |
| Albumin Revenue | 133.99B | 2.73B | 1.84B | 8.81B | 373M |
| Albumin Revenue Growth | +4817.06% | +47.86% | -79.07% | +2260.86% | n/a |
| Alofisel Revenue | 3.51B | 20.56B | 13.64B | 82.2B | 7.24B |
| Alofisel Revenue Growth | -82.91% | +50.66% | -83.40% | +1035.90% | n/a |
| Alunbrig Revenue | 28.52B | 72.9B | 76.3B | 55.57B | 76.75B |
| Alunbrig Revenue Growth | -60.87% | -4.46% | +37.29% | -27.59% | n/a |
| Azilva-F Revenue | 33.64B | 69.37B | 50.76B | 68.79B | 62.8B |
| Azilva-F Revenue Growth | -51.51% | +36.66% | -26.20% | +9.54% | n/a |
| Dexilant Revenue | 45.28B | 85.32B | 73.12B | 429.28B | 67.92B |
| Dexilant Revenue Growth | -46.93% | +16.69% | -82.97% | +532.00% | n/a |
| Elaprase Revenue | 91.56B | 702.74B | 521.78B | 777.8B | 347.2B |
| Elaprase Revenue Growth | -86.97% | +34.68% | -32.92% | +124.02% | n/a |
| Entyvio Revenue | 800.92B | 41.27B | 39.16B | 64.56B | 697.9B |
| Entyvio Revenue Growth | +1840.77% | +5.38% | -39.34% | -90.75% | n/a |
| Feiba Revenue | 40.54B | 1,094.5B | 875.68B | 34.19B | 61.81B |
| Feiba Revenue Growth | -96.30% | +24.99% | +2461.01% | -44.68% | n/a |
| Fosrenol Revenue | 13.53B | 93.08B | 75.75B | 334.87B | 31.82B |
| Fosrenol Revenue Growth | -85.46% | +22.87% | -77.38% | +952.57% | n/a |
| Gastroenterology Revenue | 1,216.2B | 47.21B | 34.86B | 417.3B | 298.7B |
| Gastroenterology Revenue Growth | +2476.38% | +35.42% | -91.65% | +39.71% | n/a |
| Gattex/Revestive Revenue | 119.25B | 522.21B | 385.86B | 87.4B | 438.52B |
| Gattex/Revestive Revenue Growth | -77.16% | +35.34% | +341.51% | -80.07% | n/a |
| Iclusig Revenue | 54.71B | 111.31B | 106.46B | 416.51B | 77.56B |
| Iclusig Revenue Growth | -50.85% | +4.56% | -74.44% | +437.05% | n/a |
| Immunoglobulin Revenue | 644.59B | 637.71B | 482.29B | 99.66B | 420.96B |
| Immunoglobulin Revenue Growth | +1.08% | +32.22% | +383.95% | -76.33% | n/a |
| Intuniv Revenue | 33.55B | 92.69B | 91.2B | 27.93B | 103.54B |
| Intuniv Revenue Growth | -63.80% | +1.63% | +226.48% | -73.02% | n/a |
| Leuplin/Enantone Revenue | 107.35B | 438.74B | 468.73B | 574.07B | 28.25B |
| Leuplin/Enantone Revenue Growth | -75.53% | -6.40% | -18.35% | +1931.88% | n/a |
| Neuroscience Revenue | 627.01B | 72.39B | 82.88B | 402.43B | 704.76B |
| Neuroscience Revenue Growth | +766.19% | -12.66% | -79.41% | -42.90% | n/a |
| Ninlaro Revenue | 87.36B | 34.79B | 31.05B | 45.31B | 538.3B |
| Ninlaro Revenue Growth | +151.14% | +12.02% | -31.47% | -91.58% | n/a |
| Oncology Revenue | 462.36B | 454.6B | 624.15B | 420.39B | 66.2B |
| Oncology Revenue Growth | +1.71% | -27.17% | +48.47% | +534.99% | n/a |
| Other Gastroenterology Revenue | 82.23B | 364.97B | 515.16B | 591.75B | 394.17B |
| Other Gastroenterology Revenue Growth | -77.47% | -29.15% | -12.94% | +50.13% | n/a |
| Other PDT Immunology Revenue | 39.99B | 46.37B | 53.01B | 289.8B | 634.89B |
| Other PDT Immunology Revenue Growth | -13.75% | -12.54% | -81.71% | -54.35% | n/a |
| Other Product Revenue | 368.91B | 678.44B | 506.95B | 51.76B | 334.24B |
| Other Product Revenue Growth | -45.62% | +33.83% | +879.35% | -84.51% | n/a |
| Other Product, Other Revenue | 321.74B | 45.52B | 40.27B | 86.72B | 51.25B |
| Other Product, Other Revenue Growth | +606.85% | +13.02% | -53.56% | +69.20% | n/a |
| Other Rare Hematology Revenue | 47.3B | 723.44B | 283.69B | 68.87B | 68.27B |
| Other Rare Hematology Revenue Growth | -93.46% | +155.01% | +311.93% | +0.88% | n/a |
| PDT Immunology Revenue | 818.57B | 304.72B | 12.3B | 101.11B | 70.67B |
| PDT Immunology Revenue Growth | +168.63% | +2377.99% | -87.84% | +43.08% | n/a |
| Pantoloc/Controloc Revenue | 46.49B | 12.76B | 51.71B | 38.52B | 118.32B |
| Pantoloc/Controloc Revenue Growth | +264.32% | -75.32% | +34.26% | -67.45% | n/a |
| Rare Diseases Revenue | 770.7B | 66.74B | 103.24B | n/a | 38.01B |
| Rare Diseases Revenue Growth | +1054.76% | -35.35% | n/a | n/a | n/a |
| Rare Hematology Revenue | 305.3B | 151.8B | 82.31B | n/a | n/a |
| Rare Hematology Revenue Growth | +101.12% | +84.41% | n/a | n/a | n/a |
| Recombinate Revenue | 12.05B | 100.08B | 110.05B | n/a | n/a |
| Recombinate Revenue Growth | -87.96% | -9.06% | n/a | n/a | n/a |
| Replagal Revenue | 73.55B | 27.76B | 42.41B | n/a | n/a |
| Replagal Revenue Growth | +164.97% | -34.54% | n/a | n/a | n/a |
| Takhzyro Revenue | 178.68B | 48.37B | 327.05B | n/a | n/a |
| Takhzyro Revenue Growth | +269.38% | -85.21% | n/a | n/a | n/a |
| Trintellix Revenue | 104.8B | 459.29B | n/a | n/a | n/a |
| Trintellix Revenue Growth | -77.18% | n/a | n/a | n/a | n/a |
| Velcade Revenue | 5.54B | n/a | n/a | n/a | n/a |
| Velcade Revenue Growth | n/a | n/a | n/a | n/a | n/a |
| Vpriv Revenue | 51.3B | n/a | n/a | n/a | n/a |
| Vpriv Revenue Growth | n/a | n/a | n/a | n/a | n/a |
| Vyvanse/Elvanse Revenue | 423.22B | n/a | n/a | n/a | n/a |
| Vyvanse/Elvanse Revenue Growth | n/a | n/a | n/a | n/a | n/a |
Operating Expense Breakdown
| Period Ending | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 270.59B | 268.28B | 270.03B | 285.23B | 267.52B | 252.95B | 248.11B | 254.8B | 262.3B | 248.73B | 231.48B | 223.43B | 231.08B | 212.01B | 219.84B | 234.39B | 222.64B | 216.26B | 202.37B | 253.06B | 249.21B | 223.26B | 239.21B | 269.92B | 153.89B | 148.75B | 145.03B | 171.77B | 159.08B | 151.4B | 145.87B | 179.69B | 148.43B | 145.98B | 144.96B | 175.25B | 162.03B | 151.8B | 161.69B | 174.58B |
| Selling, General, and Administrative Revenue Growth | +0.86% | -0.65% | -5.33% | +6.62% | +5.76% | +1.95% | -2.62% | -2.86% | +5.45% | +7.45% | +3.60% | -3.31% | +8.99% | -3.56% | -6.21% | +5.27% | +2.95% | +6.86% | -20.03% | +1.54% | +11.63% | -6.67% | -11.38% | +75.39% | +3.45% | +2.57% | -15.57% | +7.98% | +5.07% | +3.79% | -18.82% | +21.06% | +1.68% | +0.71% | -17.29% | +8.16% | +6.74% | -6.12% | -7.38% | n/a |
| Research and Development Revenue | 170.19B | 175.56B | 168.46B | 195.86B | 187.38B | 183.95B | 162.74B | 160.94B | 174.63B | 154.15B | 143.61B | 143.63B | 128.38B | 131.6B | 122.48B | 113.29B | 117.57B | 118.16B | 106.82B | 139.31B | 122.71B | 113.5B | 116.87B | 139.41B | 77.46B | 79.47B | 71.97B | 88.78B | 81.56B | 79.41B | 75.69B | 88.5B | 71.83B | 75.42B | 76.55B | 92.03B | 92.53B | 80.38B | 80.99B | 132.87B |
| Research and Development Revenue Growth | -3.06% | +4.22% | -13.99% | +4.52% | +1.87% | +13.03% | +1.12% | -7.84% | +13.29% | +7.34% | -0.01% | +11.88% | -2.45% | +7.45% | +8.11% | -3.64% | -0.50% | +10.61% | -23.32% | +13.53% | +8.12% | -2.88% | -16.17% | +79.97% | -2.52% | +10.42% | -18.94% | +8.85% | +2.72% | +4.91% | -14.48% | +23.21% | -4.75% | -1.48% | -16.82% | -0.54% | +15.11% | -0.75% | -39.04% | n/a |